Hidoc Dr | Medical Learning App for Doctors

Today's Updates

Baseline RV Dysfunction May predict Sotatercept response in PAH

Published Date: 05 Nov 2026

Baseline RV Dysfunction May predict Sotatercept response in PAH

FDA Grants Priority Review to Huntington Disease Gene Therapy BLA Marco Meglio

Published Date: 05 Nov 2026

The FDA accepted uniQure's biologics license application for ifezuntirgene inilparvovec and granted it Priority Review, setting a target action date of May 1, 2027.

On Beyond Seizures: Unmet Needs in Pediatric Epilepsy Clinics Susan Duberstein, MD

Published Date: 05 Nov 2026

Pediatric epilepsy care goes beyond seizures, addressing mental health, learning needs, coordinated referrals, equitable access, and smoother transition to adult services.

Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development Marco Meglio

Published Date: 05 Nov 2026

Sabirnetug failed to meet its primary endpoint in Acumen Pharmaceuticals' phase 2 ALTITUDE-AD trial for early Alzheimer disease, prompting the company to end development.

AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS Marco Meglio

Published Date: 05 Nov 2026

AL-S Pharma outlined the design of AP101-03, a planned phase 3 trial of AP-101 in sporadic and SOD1-associated ALS, at the 2026 NEALS Annual Meeting.

Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study Louie Pasculli

Published Date: 05 Nov 2026

Alnylam Pharmaceuticals reported initial Phase 1b findings showing brezosiran reduced cerebrospinal fluid mutant huntingtin levels by a mean of 60% to 64% at 3 months, with plans for a pivotal study in 2027.

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease Isabella Ciccone, MPH, Cindy Zadikoff, MD, MSc

Published Date: 05 Nov 2026

The executive medical director at AbbVie discussed the FDA approval of tavapadon, the first D1/D5 dopamine agonist for Parkinson disease, including the supporting TEMPO trial data and safety considerations.

Bioengineered Vessel for Dialysis Access Integrates With Patient Cells

Published Date: 05 Nov 2026

Bioengineered Vessel for Dialysis Access Integrates With Patient Cells

Bioengineered Vessel Adds 91 Catheter-Free Days for Women on Dialysis

Published Date: 05 Nov 2026

Bioengineered Vessel Adds 91 Catheter-Free Days for Women on Dialysis

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Published Date: 05 Nov 2026

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Knowledge Hub

Oncology

Engineered Lymphoid Tissue Niches for Reconstructing Immune-Supportive Microenvironments After Cancer Treatment

A medical review of engineered lymphoid tissue niches for restoring immune function after cancer treatment, including mechanisms, clinical applications, risks, and emerging research.

Oncology

Monitoring Delayed Toxicities of Cellular Cancer Therapies

A clinical review of delayed toxicities after cellular cancer therapy, including mechanisms, risk factors, diagnosis, management, and guideline-based long-term surveillance.

Oncology

Genomic Determinants of Tumor Cell Dormancy in Minimal Residual Cancer Disease

A medical review of genomic, epigenetic, immune, and microenvironmental mechanisms governing tumor dormancy in minimal residual cancer disease.

Oncology

Therapeutic Advances in Tumor Nutrient-Deprivation Strategies

A medical review of tumor nutrient-deprivation therapies, including mechanisms, clinical applications, emerging treatments, safety, biomarkers, and future directions.

Oncology

KOL Videos

Hidoc Dr| Hidoc- US| Hidoc - Doctor Netwoking Platform| Educational resource for HCPs

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug Database Drug Interaction Diseases Database

KOL Videos Knowledge Hub Quizzes

Medical Updates Events About Us

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Baseline RV Dysfunction May predict Sotatercept response in PAH

FDA Grants Priority Review to Huntington Disease Gene Therapy BLA Marco Meglio

On Beyond Seizures: Unmet Needs in Pediatric Epilepsy Clinics Susan Duberstein, MD

Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development Marco Meglio

AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS Marco Meglio

Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study Louie Pasculli

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease Isabella Ciccone, MPH, Cindy Zadikoff, MD, MSc

Bioengineered Vessel for Dialysis Access Integrates With Patient Cells

Bioengineered Vessel Adds 91 Catheter-Free Days for Women on Dialysis

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Knowledge Hub

Engineered Lymphoid Tissue Niches for Reconstructing Immune-Supportive Microenvironments After Cancer Treatment

Monitoring Delayed Toxicities of Cellular Cancer Therapies

Genomic Determinants of Tumor Cell Dormancy in Minimal Residual Cancer Disease

Therapeutic Advances in Tumor Nutrient-Deprivation Strategies

Virtual Oncology Survivorship Support Networks: Evidence, Clinical Integration, and Future Directions

Precision Selection of Cancer Surgery Versus Organ-Preserving Treatment Using Patient-Specific Functional Priorities

Pathophysiology of Tumor Interstitial Fluid Accumulation

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Page Views

Your one-stop Solution for MEDICAL LEARNING & UPDATES

Baseline RV Dysfunction May predict Sotatercept response in PAH

FDA Grants Priority Review to Huntington Disease Gene Therapy BLA Marco Meglio

On Beyond Seizures: Unmet Needs in Pediatric Epilepsy Clinics Susan Duberstein, MD

Alzheimer Agent Sabirnetug Misses Primary Endpoint, Acumen Halts Development Marco Meglio

AL-S Pharma Details Planned Phase 3 Trial Design for AP-101 in ALS Marco Meglio

Brezosiran Demonstrates Mutant Huntingtin Reduction in Phase 1b Huntington Disease Study Louie Pasculli

NeuroVoices: Cindy Zadikoff, MD, MSc, on the FDA Approval of Tavapadon for Parkinson Disease Isabella Ciccone, MPH, Cindy Zadikoff, MD, MSc

Bioengineered Vessel for Dialysis Access Integrates With Patient Cells

Bioengineered Vessel Adds 91 Catheter-Free Days for Women on Dialysis

Clinician FAQ: Using Remibrutinib (Rhapsido) for Symptomatic Dermographism

Knowledge Hub

Engineered Lymphoid Tissue Niches for Reconstructing Immune-Supportive Microenvironments After Cancer Treatment

Monitoring Delayed Toxicities of Cellular Cancer Therapies

Genomic Determinants of Tumor Cell Dormancy in Minimal Residual Cancer Disease

Therapeutic Advances in Tumor Nutrient-Deprivation Strategies

Virtual Oncology Survivorship Support Networks: Evidence, Clinical Integration, and Future Directions

Precision Selection of Cancer Surgery Versus Organ-Preserving Treatment Using Patient-Specific Functional Priorities

Pathophysiology of Tumor Interstitial Fluid Accumulation

KOL Videos

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part V

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part IV

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part III

An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion

Breaking Ground: ALK-Positive Lung Cancer Front-Line Management - Part II

An In-Depth Look At The Signs And Symptoms Of Lymphoma- Further Discussion

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part VIII

Current Scenario of Cancer- Q&A Session to Close the Gap Part II

Quick Links

Verification

Welcome to Hidoc Dr.

Page Views